BR112017028137B1 - Uso de 4-[2-fluoro-4-[[[(2-fenilacetil)amino]tioxometil]amino]- fenóxi]-7-metóxi-n-metil-6-quinolinacarboxamida ou um sal deste - Google Patents

Uso de 4-[2-fluoro-4-[[[(2-fenilacetil)amino]tioxometil]amino]- fenóxi]-7-metóxi-n-metil-6-quinolinacarboxamida ou um sal deste Download PDF

Info

Publication number
BR112017028137B1
BR112017028137B1 BR112017028137-6A BR112017028137A BR112017028137B1 BR 112017028137 B1 BR112017028137 B1 BR 112017028137B1 BR 112017028137 A BR112017028137 A BR 112017028137A BR 112017028137 B1 BR112017028137 B1 BR 112017028137B1
Authority
BR
Brazil
Prior art keywords
fibrosis
amino
present
fibrillation
acid
Prior art date
Application number
BR112017028137-6A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112017028137A2 (pt
Inventor
Akio Fujioka
Original Assignee
Taiho Pharmaceutical Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co., Ltd filed Critical Taiho Pharmaceutical Co., Ltd
Publication of BR112017028137A2 publication Critical patent/BR112017028137A2/pt
Publication of BR112017028137B1 publication Critical patent/BR112017028137B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112017028137-6A 2015-06-25 2016-06-24 Uso de 4-[2-fluoro-4-[[[(2-fenilacetil)amino]tioxometil]amino]- fenóxi]-7-metóxi-n-metil-6-quinolinacarboxamida ou um sal deste BR112017028137B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015-127788 2015-06-25
JP2015127788 2015-06-25
PCT/JP2016/068902 WO2016208744A1 (ja) 2015-06-25 2016-06-24 線維症治療剤

Publications (2)

Publication Number Publication Date
BR112017028137A2 BR112017028137A2 (pt) 2018-08-28
BR112017028137B1 true BR112017028137B1 (pt) 2023-04-04

Family

ID=57585165

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017028137-6A BR112017028137B1 (pt) 2015-06-25 2016-06-24 Uso de 4-[2-fluoro-4-[[[(2-fenilacetil)amino]tioxometil]amino]- fenóxi]-7-metóxi-n-metil-6-quinolinacarboxamida ou um sal deste

Country Status (20)

Country Link
US (4) US10449189B2 (cg-RX-API-DMAC10.html)
EP (2) EP3315131B1 (cg-RX-API-DMAC10.html)
JP (3) JP6974167B2 (cg-RX-API-DMAC10.html)
KR (1) KR102647942B1 (cg-RX-API-DMAC10.html)
CN (2) CN107708697B (cg-RX-API-DMAC10.html)
AU (1) AU2016284531B2 (cg-RX-API-DMAC10.html)
BR (1) BR112017028137B1 (cg-RX-API-DMAC10.html)
CA (1) CA2990791A1 (cg-RX-API-DMAC10.html)
DK (1) DK3315131T3 (cg-RX-API-DMAC10.html)
ES (1) ES2928684T3 (cg-RX-API-DMAC10.html)
HU (1) HUE060732T2 (cg-RX-API-DMAC10.html)
MA (1) MA42266A (cg-RX-API-DMAC10.html)
MX (2) MX381792B (cg-RX-API-DMAC10.html)
MY (1) MY191219A (cg-RX-API-DMAC10.html)
PH (1) PH12017502322B1 (cg-RX-API-DMAC10.html)
PL (1) PL3315131T3 (cg-RX-API-DMAC10.html)
PT (1) PT3315131T (cg-RX-API-DMAC10.html)
RU (1) RU2729630C2 (cg-RX-API-DMAC10.html)
SG (2) SG10201912684TA (cg-RX-API-DMAC10.html)
WO (1) WO2016208744A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007139608A1 (en) 2006-03-14 2007-12-06 Ceres, Inc. Nucleotide sequences and corresponding polypeptides conferring modulated growth rate and biomass in plants grown in saline conditions
US12152246B2 (en) 2006-03-14 2024-11-26 Ceres, Inc. Nucleotide sequences and corresponding polypeptides conferring modulated growth rate and biomass in plants grown in saline conditions
BR112017028137B1 (pt) * 2015-06-25 2023-04-04 Taiho Pharmaceutical Co., Ltd Uso de 4-[2-fluoro-4-[[[(2-fenilacetil)amino]tioxometil]amino]- fenóxi]-7-metóxi-n-metil-6-quinolinacarboxamida ou um sal deste
DK3583943T3 (da) 2017-02-15 2024-10-14 Taiho Pharmaceutical Co Ltd Farmaceutisk sammensætning
EP3682882A4 (en) 2017-09-08 2021-06-02 Taiho Pharmaceutical Co., Ltd. ANTI-TUMOR AGENT AND ANTI-TUMOR POTENTIALIZER
KR20210060465A (ko) 2018-09-18 2021-05-26 다이호야쿠힌고교 가부시키가이샤 아실티오우레아 화합물과 아비라테론의 병용 요법
TWI872203B (zh) * 2020-02-14 2025-02-11 日商大鵬藥品工業股份有限公司 醯基硫脲化合物的製造方法
CN115177636A (zh) * 2022-07-18 2022-10-14 陕西科美致尚生物科技有限公司 一种用于治疗前列腺钙化的组合物及其制备方法与应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4094814B2 (ja) 1998-04-28 2008-06-04 敏一 中村 血管新生抑制剤
JP2003238592A (ja) * 2001-12-13 2003-08-27 Japan Tobacco Inc 組織及び血管の再生のための医薬及びその方法
EP1896461A2 (en) 2005-06-30 2008-03-12 Amgen Inc. Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
ZA200804681B (en) * 2005-11-30 2009-11-25 Vertex Pharma Inc Inhibitors of C-Met and uses thereof
US7728017B2 (en) * 2005-11-30 2010-06-01 Vertex Pharmaceuticals Incorporated Inhibitors of c-Met and uses thereof
CA2676173A1 (en) 2007-02-16 2008-08-28 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
EP2215085B1 (en) * 2007-10-25 2011-09-07 AstraZeneca AB Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
JP4667537B2 (ja) 2008-04-10 2011-04-13 大鵬薬品工業株式会社 アシルチオウレア化合物又はその塩、及びその用途
UY32049A (es) * 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
MX2012008898A (es) * 2010-02-03 2012-11-06 Incyte Corp Imidazo - [1, 2 - b] [1, 2, 4] triazinas como inhibidores de c - met.
JP5960688B2 (ja) 2010-05-17 2016-08-02 インコゼン セラピューティクス プライベート リミテッド プロテインキナーゼ調節物質としての新規3,5−二置換−3h−[1,2,3]トリアゾロ[4,5−b]ピリジン化合物
TWI594986B (zh) 2011-12-28 2017-08-11 Taiho Pharmaceutical Co Ltd Antineoplastic agent effect enhancer
RU2494470C1 (ru) * 2012-04-04 2013-09-27 Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "Саентифик Фьючер Менеджмент") Способ лечения фиброза легких
US9149471B2 (en) 2013-09-30 2015-10-06 National University Corporation Tokyo University Of Agriculture And Technology Therapeutic agent for osteoporosis
BR112017028137B1 (pt) * 2015-06-25 2023-04-04 Taiho Pharmaceutical Co., Ltd Uso de 4-[2-fluoro-4-[[[(2-fenilacetil)amino]tioxometil]amino]- fenóxi]-7-metóxi-n-metil-6-quinolinacarboxamida ou um sal deste

Also Published As

Publication number Publication date
US20220047572A1 (en) 2022-02-17
JPWO2016208744A1 (ja) 2018-04-12
KR20180021682A (ko) 2018-03-05
SG10201912684TA (en) 2020-03-30
KR102647942B1 (ko) 2024-03-14
AU2016284531A1 (en) 2017-11-30
ES2928684T3 (es) 2022-11-21
PH12017502322B1 (en) 2023-08-30
US10449189B2 (en) 2019-10-22
US20200297716A1 (en) 2020-09-24
PT3315131T (pt) 2022-10-26
EP3315131B1 (en) 2022-09-14
EP3315131A1 (en) 2018-05-02
US11191759B2 (en) 2021-12-07
SG11201709260TA (en) 2018-01-30
MX2017016774A (es) 2018-05-14
DK3315131T3 (da) 2022-11-14
US20180289690A1 (en) 2018-10-11
CN112716952A (zh) 2021-04-30
MY191219A (en) 2022-06-09
JP2022009994A (ja) 2022-01-14
RU2017145271A (ru) 2019-07-25
WO2016208744A1 (ja) 2016-12-29
BR112017028137A2 (pt) 2018-08-28
HUE060732T2 (hu) 2023-04-28
MX381792B (es) 2025-03-13
US11690838B2 (en) 2023-07-04
JP6974167B2 (ja) 2021-12-01
RU2017145271A3 (cg-RX-API-DMAC10.html) 2019-12-02
PH12017502322A1 (en) 2018-06-25
US10695340B2 (en) 2020-06-30
HK1245639A1 (zh) 2018-08-31
MA42266A (fr) 2018-05-02
EP3315131A4 (en) 2019-02-27
MX2020012989A (es) 2021-02-16
JP7498827B2 (ja) 2024-06-12
AU2016284531B2 (en) 2020-06-04
JP7258985B2 (ja) 2023-04-17
EP3973962A1 (en) 2022-03-30
JP2023076632A (ja) 2023-06-01
CN107708697B (zh) 2021-02-09
CN107708697A (zh) 2018-02-16
US20200009128A1 (en) 2020-01-09
RU2729630C2 (ru) 2020-08-11
CA2990791A1 (en) 2016-12-29
PL3315131T3 (pl) 2022-12-12

Similar Documents

Publication Publication Date Title
US11690838B2 (en) Therapeutic agent for fibrosis
EP3377064B1 (en) Orvepitant for the treatment of chronic cough
BR112020002646A2 (pt) compostos e composições farmacêuticas dos mesmos para uso no tratamento de doenças fibróticas
EP3858351B1 (en) Tolperisone and eperisone for use in the treatment of pulmonary fibrosis
WO2012163088A2 (zh) 肾病和心脏病的治疗药物及其用途
JP6908936B2 (ja) セレノプロテインp活性阻害作用を有する成分を含有する、肺高血圧症の予防又は治療剤
HK40046439A (en) Therapeutic agent for fibrosis
CA2487356A1 (en) 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating pulmonary fibrosis
CN121443299A (zh) 用于治疗脏器纤维化相关疾病的药物组合物和方法
HK1245639B (en) Therapeutic agent for fibrosis
KR20240168338A (ko) 호흡기 질환 치료제
WO2007123126A1 (ja) 慢性心不全における運動耐容能低下の改善剤
BR112019005039B1 (pt) Método de redução dos efeitos colaterais associados à tireoide
WO2017204163A1 (ja) 肺障害の予防または抑制用医薬

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/06/2016, OBSERVADAS AS CONDICOES LEGAIS